Joel Epstein
Pulmonary Disease · Lakewood, CANPI 1013037779
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,127 of the $4,722 with a category attached, or 87.4%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,848 and has fallen 94.7% since, to $98 in 2023.
Across 238 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- GSK$741
- AstraZeneca$712
- AbbVie$627
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$412
- Mylan Specialty L.p.$400
- plus $822 from 17 others
What the payments were for
- Speaking & faculty fees$58312%
- Food & beverage$4,12787%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 46 | $1,007 |
| GSK | 47 | $741 |
| AstraZeneca | 38 | $712 |
| AbbVie(2 entities) | 4 | $627 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $412 |
| Mylan Specialty L.p. | 22 | $400 |
| Regeneron Healthcare Solutions, Inc. | 6 | $171 |
| Philips North America LLC | 6 | $107 |
| Merck | 5 | $89 |
| Sanofi | 3 | $70 |
| Advanced Respiratory, Inc | 2 | $58 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Actelion Pharmaceuticals US, Inc. | 3 | $47 |
| Electromed, Inc. | 3 | $41 |
| United Therapeutics Corporation | 2 | $36 |
| Pulmonx Corporation | 2 | $29 |
| Gilead | 1 | $25 |
| Johnson & Johnson | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $12 |
| Inogen, Inc. | 1 | $6 |
How this compares
$4,722 in reported general payments places this provider in the 70th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Lakewood
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.